visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration |
Fecha: | 2023 |
Resumen: | Nanoparticle (NP) pharmacokinetics significantly differ from traditional small molecule principles. From this emerges the need to create new tools and concepts to harness their full potential and avoid unnecessary risks. Nanoparticle pharmacokinetics strongly depend on size, shape, surface functionalisation, and aggregation state, influencing their biodistribution, accumulation, transformations, and excretion profile, and hence their efficacy and safety. Today, while NP biodistribution and nanoceria biodistribution have been studied often at short times, their long-term accumulation and excretion have rarely been studied. In this work, 3 nm nanoceria at 5. 7 mg/kg of body weight was intravenously administrated in a single dose to healthy mice. Biodistribution was measured in the liver, spleen, kidney, lung, brain, lymph nodes, ovary, bone marrow, urine, and faeces at different time points (1, 9, 30, and 100 days). Biodistribution and urinary and faecal excretion were also studied in rats placed in metabolic cages at shorter times. The similarity of results of different NPs in different models is shown as the heterogeneous nanoceria distribution in organs. After the expectable accumulation in the liver and spleen, the concentration of cerium decays exponentially, accounting for about a 50% excretion of cerium from the body in 100 days. Cerium ions, coming from NP dissolution, are most likely excreted via the urinary tract, and ceria nanoparticles accumulated in the liver are most likely excreted via the hepatobiliary route. In addition, nanoceria looks safe and does not damage the target organs. No weight loss or apathy was observed during the course of the experiments. |
Ayudas: | Agencia Estatal de Investigación RTI2018-099965-B-I00 Agencia Estatal de Investigación PCI2019-103436 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1431 Agencia Estatal de Investigación SEV-2017-0706 Agència de Gestió d'Ajuts Universitaris i de Recerca 2016/BP-00350 Ministerio de Ciencia e Innovación RYC2019-026522-I Agencia Estatal de Investigación RTI2018-094734-B-C21 Instituto de Salud Carlos III PI19/00774 |
Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Lengua: | Anglès |
Documento: | Article ; recerca ; Versió publicada |
Materia: | Nanoceria ; Nanoparticle biodistribution ; Nanopharmacokinetics ; Nanosafety ; NP dissolution ; NP excretion ; NP long-term accumulation |
Publicado en: | Antioxidants, Vol. 12, Issue 3 (March 2023) , art. 765, ISSN 2076-3921 |
20 p, 4.6 MB |